Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

Author： Kolitz Jonathan E.   George Stephen L.   Benson Don M.   Maharry Kati   Marcucci Guido   Vij Ravi   Powell Bayard L.   Allen Steven L.   DeAngelo Daniel J.   Shea Thomas C.   Stock Wendy   Bakan Courtney E.   Hars Vera   Hoke Eva   Bloomfield Clara D.   Caligiuri Michael A.   Larson Richard A.    

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|7|1010-1017

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.7, 2014-04, pp. : 1010-1017

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?

By Grosso Dolores   Weiss Mark A.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 940-941

Blackwell Publishing

Access to resources Recommend Favorite

Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

By Kimmick Gretchen   Ratain Mark J.   Berry Don   Woolf Susan   Norton Larry   Muss Hyman B.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 83-89

Springer Publishing Company

Access to resources Recommend Favorite

Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression

By Shi Pengcheng   Zha Jie   Guo Xutao   Chen Feili   Fan Zhiping   Huang Fen   Meng Fanyi   Liu Xiaoli   Feng Ru   Xu Bing  

Pharmacogenomics, Vol. 14, Iss. 1, 2013-01 ,pp. : 17-23

Future Medicine

Access to resources Recommend Favorite

Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia

By  

Drug Metabolism Letters, Vol. 4, Iss. 4, 2010-12 ,pp. : 228-232

Bentham Science Publishers

Access to resources Recommend Favorite

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

By  

Cancer, Vol. 121, Iss. 14, 2015-07 ,pp. : 2375-2382

Blackwell Publishing

Access to resources Recommend Favorite